NOXXON Pharma announces appointment of Dr. Walter Wenninger as Chairman of the Board

Berlin, (PresseBox) -

This release was saved as a PDF file. Please click on the "view PDF" link to display this report.

Display press release

You need the free Adobe Reader in order to display this release.

Download Adobe Reader


Noxxon Pharma AG

Based on one of best protected technology platforms in the industry, NOXXON Pharma AG develops biostable aptamers, novel substances using mirror image nucleic acids. These so-called Spiegelmers® (the German word "Spiegel" means mirror) are highly specific for the pharmacologically relevant target for which they were selected. Thanks to their structural characteristics, Spiegelmers® are extremely resistant to degradation and not immunogenic - a new generation of improved therapeutics.

Press releases you might also be interested in

Subscribe for news

The subscribtion service of the PresseBox informs you about press information of a certain topic by your choice at a choosen time. Please enter your email address to receive the email with the press releases.

An error occurred!

Thank you! You will receive a confirmation email within a few minutes.


I want to subscribe to the gratis press mail and have read and accepted the conditions.